Mr. Gilles Brisson to join Cytomics Systems’ Supervisory Board

Gif-sur-Yvette (France) - May 29, 2007 - CYTOMICS SYSTEMS, a privately-held development stage company with proprietary expertise in protein degradation pathways, today announced the appointment of Mr. Gilles Brisson formerly with Aventis and Sanofi-Aventis as a member of its Supervisory Board.

“It’s a real pleasure for us to welcome Gilles to our Board. His long-standing experience in general management, global corporate development, commercial operations and public affairs within the pharmaceutical sector is a unique asset to help shaping the future of the company”, said Thierry Hercend, MD., PhD., Chairman of the Supervisory Board.

Gilles Brisson has been Chairman of the Management board of Aventis Pharma S.A. since 1999 and then Chairman of its supervisory board. Mr Brisson, who joined the pharmaceutical division of the Rhône-Poulenc group in 1980, has assumed different operational responsibilities in France, Europe and Japan and was Senior Vice President Corporate Development of Rhône-Poulenc Rorer. He was in charge of commercial operations in France for Aventis where he has served as Corporate Senior Vice President of worldwide Communications and for Public Affairs. He was then responsible for Europe commercial operations. Mr Brisson had similar responsibilities for the Sanofi-Aventis group. He was previously director of marketing at SMO and Smith Corona-Marchant Corp. Mr Brisson is a graduate of HEC (1973), a leading French business school.

Bernard Cambou, PhD., Chairman of the Management Board commented: “We evolve in a very competitive environment where business and corporate considerations are as critical as our ability to deliver good science. In that context, M. Gilles Brisson’s involvement brings a great deal of proven experience. We praise his desire to participate actively into the build up of emerging biotech companies and we are fortunate that he has accepted to join our Supervisory Board.”

Gilles Brisson added: “I am very happy to join the Supervisory Board of Cytomics to try to help the management team for whom I have a lot of respect and who intends to turn some breakthrough scientific discovery in the field of the ubiquitin-proteasome pathway into potential products in the field of cancer and anti-fungals. This is a very interesting area and it is very exciting to try these new approaches for the benefit of patients who suffer from life threatening diseases.”

About CYTOMICS SYSTEMS
CYTOMICS SYSTEMS is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases such as cancer and fungal infections. The Company was founded by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics, and internationally recognized for his work in the field of the Ubiquitin-Proteasome pathway for protein degradation.

The Company has developed an innovative high-throughput screening technology, UbiScreen®, for the discovery of new therapeutic molecules controlling the degradation of target proteins. CYTOMICS SYSTEMS has used this technology to target fungal infections with compounds at the preclinical stage. Another drug development program in the field of oncology has led to the selection of very promising molecules.

The company is based in Gif-sur-Yvette (France) and has 15 employees. In February 2006, Edmond de Rothschild Investment Partners was joined by Truffle Venture and previous investor, Societe Generale Asset Management, in providing CYTOMICS SYSTEMS with a €10M Series-B investment. ( www.cytomics.fr )

Contacts:

CYTOMICS SYSTEMS
Erwan MARTIN, CFO
Tél.: +33 (0)1 69 82 42 46
E-mail: emartin@cytomics.fr

MILESTONES – Press Relations
Bruno ARABIAN
Tél.: +33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26
E-mail: milestones@milestones-fr.com